Market cap
₹24 Cr
Revenue (TTM)
₹87 Cr
P/E Ratio
27.8
P/B Ratio
0.8
Div. Yield
0 %
Stock Range
Today’s Range
52 Week Range
Liquidity
Fundamentals
-
Net Profit (TTM)
₹1 Cr
-
ROE
3.1 %
-
ROCE
6.7 %
-
Industry P/E
43.37
-
EV/EBITDA
11
-
Debt to Equity
0.7
-
Book Value
₹37.9
-
EPS
₹1.1
-
Face value
10
-
Shares outstanding
7,545,056
10 Years Aggregate
CFO
₹8.02 Cr
EBITDA
₹21.84 Cr
Net Profit
₹7.33 Cr
Performance
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Chandra Pharma
| -23.4 | -1.3 | -25.1 | -- | -34.0 | -8.6 | -- |
|
BSE Healthcare*
| 7.1 | 11.7 | 10.9 | 10.9 | 26.2 | 14.1 | 11.7 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
2021
|
|---|---|---|---|---|---|
|
Chandra Pharma
| -37.5 | -40.4 | 3.6 | 25.6 | 100.0 |
|
BSE Small Cap
| -6.6 | 29.0 | 47.5 | -1.8 | 62.8 |
|
BSE Healthcare
| -3.3 | 43.1 | 37.0 | -12.1 | 20.9 |
Essential Checks
View DetailsIs there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Financials
View DetailsKey Ratios
View Details
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Peers
View DetailsCompany |
Price (₹) | Market Cap (₹ Cr) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Chandra Pharma
|
31.6 | 23.8 | 86.7 | 0.9 | -- | 3.1 | 27.8 | 0.8 |
| 2,734.3 | 22,376.6 | 1,339.4 | 356.4 | 33.2 | 23.2 | 62.8 | 13.5 | |
| 488.2 | 18,680.8 | 2,051.5 | 180.5 | 11.6 | 7.7 | 92.6 | 4.9 | |
| 753.0 | 18,644.2 | 5,365.6 | 595.0 | 16.6 | 13.3 | 31.3 | 3.7 | |
| 1,008.2 | 16,065.1 | 7,918.4 | 429.9 | 10.7 | 7.2 | 37.1 | 2.4 | |
| 1,174.7 | 21,027.5 | 4,560.2 | 1,544.6 | 35.1 | 19.2 | 13.5 | 2.4 | |
| 1,835.2 | 21,047.8 | 1,419.3 | 20.1 | 8.4 | 0.5 | 1047.1 | 3.6 | |
| 179.9 | 23,893.2 | 8,869.1 | -383.1 | 1.0 | -4.2 | -- | 2.9 | |
| 458.1 | 18,488.1 | 3,738.7 | 316.7 | 12.5 | 7.5 | 58.4 | 3.8 | |
| 1,606.5 | 26,110.9 | 3,373.0 | 199.0 | 12.6 | 5.9 | 122.6 | 5.3 |
Shareholding Pattern
View DetailsNews & Analysis
All NewsNo Review & Analysis are available.
About Chandra Pharma
Manufacture of pharmaceuticals, medicinal chemical and botanical products
-
Incorporated
2003
-
Chairman
Hemant Chandravadan Bhagat
-
Managing Director
Hemant Chandravadan Bhagat
-
Headquarters
Mumbai, Maharashtra
-
Website
Looking for more details about Chandra Bhagat Pharma Ltd.’s IPO? Explore our IPO Details page.
Annual Reports
Announcements
View AnnouncementsNo News & Announcements are available.
FAQs for Chandra Pharma
What is the current share price of Chandra Bhagat Pharma Ltd Today?
The share price of Chandra Bhagat Pharma Ltd is ₹31.60 (BSE) as of 06-May-2026 IST. Chandra Bhagat Pharma Ltd has given a return of -34% in the last 3 years.
What is the current PB & PE ratio of Chandra Bhagat Pharma Ltd?
The P/E ratio of Chandra Bhagat Pharma Ltd is 27.79 times as on 06-May-2026, a 36 discount to its peers’ median range of 43.37 times.
The P/B ratio of Chandra Bhagat Pharma Ltd is 0.83 times as on 06-May-2026, a 77 discount to its peers’ median range of 3.67 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2025
|
46.03
|
1.38
|
|
2024
|
46.84
|
2.59
|
|
2023
|
80.83
|
2.85
|
|
2022
|
107.78
|
3.38
|
|
2021
|
157.34
|
1.22
|
What is the 52 Week High and Low of Chandra Bhagat Pharma Ltd?
The 52-week high and low of Chandra Bhagat Pharma Ltd are Rs 61.50 and Rs 29.70 as of 09-May-2026.
What is the market cap of Chandra Bhagat Pharma Ltd?
Chandra Bhagat Pharma Ltd has a market capitalisation of ₹ 24 Cr as on 06-May-2026. As per SEBI classification, it is a Small Cap company.
Should I invest in Chandra Bhagat Pharma Ltd?
Before investing in Chandra Bhagat Pharma Ltd, assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.